Deloitte Recap
Presents
ALLICENSE 2010
Redefining the Threshold of Innovation
May 25 & 26, 2010
Fairmont Hotel, San Francisco, CA
Agenda
| 8:00 – 8:15 |
Introduction & Welcoming Remarks
• Michael G. McCully, Deloitte Recap LLC |
| 8:15 – 9:15 |
Keynote Presentation 1: Lessons from 60 Years of Pharmaceutical Innovation
• Bernard Munos, Advisor, Corporate Strategy, Eli Lilly |
| 9:15 – 10:45 |
Session 1: Organizational Strategies to Speed Development and Decision Making
• Session Chair: Bernard Munos, Advisor, Corporate Strategy, Eli Lilly
• James Sabry, VP Genentech Partnering, Genentech
• Gino Santini, SVP Corporate Development, Eli Lilly
• R. Christopher Seaton, SVP Global Transactions, Bayer Healthcare Pharmaceuticals
• Klaus Wilgenbus, Corporate SVP, Boehringer Ingelheim |
| 10:45 – 11:15 |
Morning Break |
| 11:15 – 12:00 |
Session 2: The CEO Perspective: Maintaining a Culture of Innovation
• Session Chair: Mike G. McCully, Deloitte Recap LLC
• Paul J. Hastings, President & CEO, OncoMed Pharmaceuticals
• Arlene Morris, CEO, Affymax
|
| 12:00 – 1:30 |
Luncheon
|
| 1:30 – 2:15 |
Keynote Presentation 2: Lessons on Successfully Developing Disruptive Technologies
• John Mendlein, Chairman, Fate Therapeutics |
| 2:15 – 3:15 |
Session 3: Building a Company for the Long Haul, When Investors Focus on the
Near Term
• Session Chair: Kingsley Taft, Partner, Goodwin Procter LLP
• Katrine Bosley, CEO, Avila Therapeutics
• Cláudia Hirawat, SVP, Corporate Development, PTC Therapeutics
• Jeff Jonker, J.D., Chief Business Officer, Satori Pharmaceuticals
|
| 3:15- 3:45 |
Afternoon Break |
| 3:45 – 4:15 |
Case Study 1: Seattle Genetics
• Eric Dobmeier, Chief Business Officer, Seattle Genetics
|
| 4:15 – 4:45 |
Case Study 2: Amylin Pharmaceuticals
• Kelly Powell, Senior Director, Amylin Pharmaceuticals
|
| 4:45 – 6:00 |
Session 4: Where are we Going? The Future for Pharma Biotech Alliances
• Session Chair: Robert Silverman, Global Licensing Director, Roche
• Graham R. Brazier, VP Strategic Transactions, Bristol Myers Squibb
• Daniel J. Curran, M.D., VP, Corporate Development, Millennium: The Takeda Oncology Company
• Michael Lytton, EVP, Business and Corporate Development, Biogen Idec
• Barbara Yanni, VP & Chief Licensing Officer, Merck & Co. |
|
|
ALLICENSE 2010 Breakthrough Alliance Awards Dinner
Fairmont Hotel
6:00 - 7:00
Pre-Dinner Cocktails
7:00 - 8:30
Dinner and Awards Ceremony, The Venetian Room
Post-Dinner Networking Reception, Crown Room
Please join us for an enjoyable evening of networking and celebration!
All registered attendees are invited |
|
|
| 8:00 – 8:30 |
Analyzing the Data and Trends 1: What is Pharma Looking For?
• Michael G. McCully, Deloitte Recap LLC |
| 8:30 – 9:30 |
Session 5: Early Stage Risk Sharing Models for Pharma and Biotech
• Session Chair: Timothy F. Herpin Ph.D., Director, Search and Evaluation, Bristol-Myers Squibb
• Allen Downs, Senior Executive Director, Licensing & Business Development, Purdue Pharma
• Jeremy Grunstein, Director, Strategy & Corporate Development, Amgen
• Polly Murphy, VP, R&D Business Development, Pfizer |
| 9:30 – 10:30 |
Session 6: Running an Effective Transaction Process
• Session Chair: Fran Heller, EVP, Business Development, Exelixis
• David C. Hastings, EVP, Chief Financial Officer, Incyte Corporation
• Hoyoung Huh, M.D., Ph.D., Chairman, BiPar Sciences
• Raul Rodriguez, EVP and Chief Operating Officer, Rigel |
| 10:30 – 11:00 |
Morning Break |
| 11:00 – 12:00 |
Session 7: Late Stage Deals Designed to Create a ‘Win-Win’
• Session Chair: Randall Sunberg, Vice Chair, Life Sciences Practice, Morgan Lewis
• Brent Bankosky, Director Global Business Development, Takeda
• Jeffrey Brennan, SVP & CBO, Business & Commercial Development, Targacept Pharmaceuticals
• Rinko Ghosh, SVP and CBO, Nektar Therapeutics
• Augustine Yee, Senior Director, Global Corporate Business Development, AstraZeneca Pharmaceuticals |
| 12:00 – 1:30 |
Luncheon
|
| 1:30 – 2:00 |
Keynote Presentation 3: Carrots, Sticks & Do-Overs: Incentives in Clinical Alliances
• Mark Edwards, Managing Director, Deloitte Recap LLC and Founder, Recombinant Capital |
| 2:00 – 2:20 |
Analyzing the Data and Trends 2: What Can We Learn From Recap Data About Late-Stage Drug Development Failures?
• Lisa Natanson, Deloitte Recap LLC
|
| 2:20 – 3:20 |
Proof of Concept: Can We Redefine the “Key Deliverable” of Exploratory Drug Development?
| 2:20 – 2:40 |
Proof of Concept: Recommendations For Best Practice
• Stephen A. Williams, M.D., Ph.D., Chief Medical Officer, SomaLogic |
| 2:40 – 3:00 |
Proof of Relevance: Establishing A Clinically and Commercially Relevant Value Proposition
• Ed Saltzman, President, Defined Health |
| 3:00 – 3:20 |
De-Risking Execution in Proof of Concept
• Peter Payne, VP, Corporate Development, Quintiles Transnational Corp. |
|
| 3:20 – 4:00 |
Session 8: Does Early Stage Drug Development Hold the Key to Higher Productivity and Efficiency?
• Session Chair: Lisa Natanson, Deloitte Recap LLC
• Peter Payne, VP, Corporate Development, Quintiles Transnational Corp
• Ed Saltzman, President, Defined Health
• Mark Waring, Consultant, Corporate Strategy
• Stephen A. Williams, M.D., Ph.D., Chief Medical Officer, SomaLogic
|
| 4:00 – 4:30 |
Afternoon Break |
| 4:30 – 5:30 |
Session 9: Outlook 2010: Financing Trends and Prospects for the Next Year
• Session Chair: George Milstein, Head of Healthcare M&A, Wedbush Pacific Growth Life Sciences
• Mark Edwards, Managing Director, Deloitte Recap LLC and Founder, Recombinant Capital
• Jim McLoughlin, Executive Director, R&D Business Development, Pfizer
• Oleg Nodelman, Portfolio Manager, Biotechnology Value Fund |
|
|
|
|